青少年MASLD:袖状胃切除与综合生活方式干预的前瞻性对照研究
本研究为单中心前瞻性平行对照研究,纳入42例12-19岁重度肥胖且活检确诊MASLD(NAS≥3)的青少年,比较袖状胃切除(VSG)与综合生活方式干预(CLI)的52周组织学及心血管代谢结局。调整分析显示VSG在NAS改善、纤维化改善及MASLD完全缓解方面均优于CLI,并带来更大幅度的体重、BMI、ALT及MRI-PDFF下降。
要点
- VSG组52周NAS改善风险差0.68(95%CI 0.45-0.91),优于CLI。
- VSG组纤维化改善风险差0.36(95%CI 0.12-0.59),完全缓解风险差0.49(95%CI 0.26-0.72)。
- VSG组体重、BMI百分位、ALT及MRI-PDFF下降幅度均显著大于CLI。
核心结论
- 在重度肥胖且活检确诊MASLD的青少年中,VSG相比CLI在52周时获得更大幅度的组织学改善,包括脂肪变和纤维化。
研究设计与样本
- 单中心、前瞻性、平行臂研究,纳入42例12-19岁重度肥胖且活检确诊MASLD(NAS≥3)的青少年,VSG组17例,CLI组25例。
- 主要终点为NAS下降≥2分且纤维化不恶化;采用重叠权重调整分析处理基线不平衡,并进行了保守的未调整意向性治疗类似分析。
主要发现
- 调整分析中,VSG相比CLI的NAS改善风险差为0.68(95%CI 0.45-0.91),纤维化改善风险差为0.36(95%CI 0.12-0.59),MASLD完全缓解风险差为0.49(95%CI 0.26-0.72)。
- VSG组体重变化百分比为-19.6%(95%CI -30.0至-9.1),95th百分位BMI变化百分比为-27.6%(95%CI -42.6至-12.7)。
- VSG组ALT变化为-54.0 U/L(95%CI -80.8至-27.1),MRI-PDFF变化为-8.0%(95%CI -13.0至-2.9)。
- 保守的未调整意向性治疗分析和配对活检完成者分析结果方向一致。
临床怎么用
- 对于重度肥胖且活检确诊MASLD的青少年,VSG可作为比CLI更有效改善52周组织学结局的候选干预方式。
局限性
- 单中心研究,样本量较小(42例),52周配对组织学完成率仅64%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adolescents with severe obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) lack prospective comparative evidence to select between bariatric surgery and intensive lifestyle intervention. AIMS: To compare 52-week histological and cardiometabolic outcomes of vertical sleeve gastrectomy (VSG) versus comprehensive lifestyle intervention (CLI). METHODS: Single-centre, prospective, parallel-arm study of adolescents aged 12-19 with severe obesity and biopsy-confirmed MASLD with NAFLD Activity Score (NAS) ≥ 3. The primary endpoint was NAS ≥ 2-point decrease without fibrosis worsening; secondary endpoints included MASH resolution, fibrosis regression, MRI proton density fat fraction (MRI-PDFF) and elastography (MRE). Overlap-weighted adjusted analysis addressed baseline imbalance. Conservative unadjusted intention-to-treat analogue analyses treated missing Week 52 histology as nonresponse and missing continuous outcomes as no change. RESULTS: Forty-two adolescents enrolled (VSG = 17; CLI = 25) and 27 (64%) completed paired Week 52 histology. In the adjusted analysis, VSG was associated with a higher probability of NAS improvement (risk difference [RD] 0.68, 95% CI 0.45-0.91), fibrosis improvement (RD 0.36, 95% CI 0.12-0.59) and complete MASLD resolution (RD 0.49, 95% CI 0.26-0.72) when compared to CLI. VSG produced greater reductions in percent weight (-19.6%, 95% CI -30.0 to -9.1), percentage of the 95th percentile BMI (-27.6%, 95% CI -42.6 to -12.7), ALT (-54.0 U/L, 95% CI -80.8 to -27.1) and MRI-PDFF (-8.0%, 95% CI -13.0 to -2.9). Findings were directionally consistent in conservative unadjusted intention-to-treat and paired-biopsy completer analyses. CONCLUSION: In this prospective cohort of adolescents with severe obesity and biopsy-confirmed MASLD, VSG achieved greater 52-week histological improvement, including steatosis and fibrosis, than CLI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: (NCT02412540).
引用
- Yodoshi T, Ollberding NJ, McNeill M, et al. Vertical Sleeve Gastrectomy Versus Comprehensive Lifestyle Intervention for Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Controlled Cohort Study. Aliment Pharmacol Ther. 2026. PMID: 42259766. doi:10.1111/apt.70766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。